Mexico enters into five-year strategic agreement with Moderna to boost mRNA vaccine stocks.[1] The agreement includes supplies of Moderna's portfolio of vaccines against respiratory diseases.[1] Unlike the US, Mexico is increasing its mRNA technology capacities in this way.[1] The agreement also includes the technology transfer of the Mexican company Liomont.[1] The aim is to improve the availability of vaccines against respiratory diseases.[1]